Two Chemotherapy Regimens Plus or Minus Bevacizumab (BETTER2)

Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors

Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin (strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy regimens in the treatment of well differentiated pancreatic neuroendocrine tumors alone or in combination with bevacizumab (beva) on progression-free survival (PFS) and compare the chemotherapy regimens alone or with beva (two by two design) on the same criteria.

Study Overview

• Status: Active, not recruiting
• Conditions: Pancreatic Cancer
• Intervention / Treatment: Drug: LV5FU2; Drug: Streptozocin; Drug: Bevacizumab; Drug: Capecitabine; Drug: Temozolomide

• Study Type: Interventional
• Enrollment (Actual): 140
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Paris, France, 75015
    • Hôpital Européen Georges Pompidou
  • Paris, France, 75012
    • Hopital Saint-Antoine
  • Paris, France, 75014
    • Hopital Cochin
  • Paris, France, 75012
    • Hôpital Croix St Simon
  • Alpes-Maritimes
    • Nice, Alpes-Maritimes, France, 06189
      • Centre Antoine Lacassagne
  • Calvados
    • Caen, Calvados, France, 14033
      • CHU de Caen
  • Côte d'Or
    • Dijon, Côte d'Or, France, 21000
      • CHU de DIJON
  • Gironde
    • Pessac, Gironde, France, 33600
      • Hôpital Haut-Lévêque
  • Haute-Garonne
    • Toulouse, Haute-Garonne, France, 31400
      • IUCT - Hôpital Rangueil
  • Hauts-de-Seine
    • Clichy, Hauts-de-Seine, France, 92110
      • Hopital Beaujon
  • Hérault
    • Montpellier, Hérault, France, 34298
      • Icm Val D'Aurelle
  • Indre-et-Loire
    • Chambray-lès-Tours, Indre-et-Loire, France, 37170
      • Hôpital Trousseau CHU Tours
  • Loire-Atlantique
    • Saint-Herblain, Loire-Atlantique, France, 44800
      • Institut de Cancérologie de l'Ouest Site René Gauducheau
  • Loiret
    • Orléans, Loiret, France, 45067
      • CHR d'Orléans
  • Maine-et-Loire
    • Angers, Maine-et-Loire, France, 49100
      • CHU Angers
  • Marne
    • Reims, Marne, France, 51092
      • Hôpital Haut-Lévêque
  • Meurthe-et-Moselle
    • Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France, 54519
      • Institut de Cancerologie de Lorraine
  • Rhône
    • Lyon, Rhône, France, 69437
      • Hôpital Edouard Herriot
  • Val De Marne
    • Villejuif, Val De Marne, France, 94805
      • Gustave Roussy
  • Île-et-Vilaine
    • Rennes, Île-et-Vilaine, France, 35000
      • Centre Eugene Marquis

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

1. Well differentiated pancreatic neuroendocrine tumor grade 1 (NET G1), grade 2 (NET G2) or grade 3 (NET G3)*

   *Grade 3 tumor must be confirmed by a pathologist of the TENpath network.

2. Indication for chemotherapy for locally advanced or metastatic disease with proven progression (at least 20% increase of tumor size on a maximum of 12 months period of follow-up) or other indication of chemotherapy following the National Thesaurus of GI Cancerology (Appendix 6) (liver involvement > 50%, symptoms related to the tumour or its metastases, Ki67>10%)
3. Patient with at least one measurable target tumor by RECIST 1.1 and that has never been irradiated
4. Patient with a life expectancy greater than 3 months
5. Men or women with performance status (ECOG) ≤ 2 (Appendix 3)
6. Age ≥ 18 years
7. Adequate hematological function: neutrophil count (ANC) ≥ 1.5x109/L, platelets greater than 75x109/L, hemoglobin greater than 10g/dl (blood transfusions are accepted to reach this level).
8. Adequate liver function: serum bilirubin lower than 3 x upper limit of normal (ULN); aminotransferases and alkaline phosphatase levels lower than 2.5 ULN (lower than 5 ULN if liver metastases), TP greater than 50 %
9. Proteinuria lower than 1g/24h, blood creatinine less than 120 μmol/L and creatinin clearance ≥ 60 ml/min as calculated by Cockroft-Gault formula Note: a negative dipstick urine analysis is sufficient.
10. Absence of active bleeding, coagulopathy or pathologic condition that would confer a high risk of bleeding
11. Prior treatment with somatostatin analogues, everolimus or sunitinib is allowed
12. Negative serum pregnancy test ≤ 72 hours before randomization (for women of childbearing potential only). Sexually active women of childbearing potential must agree to use a highly effective method of contraception or to abstain from sexual activity during the study and for at least 6 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 6 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception.
13. Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
14. Patient affiliated to a social security regimen or beneficiary of such regimen

Non inclusion criteria :

1. Disease accessible to resection or percutaneous method of destruction
2. Any known allergy or contraindication to the treatments used in the trial
3. Patients with a complete DPD deficiency; defined as an uracil concentration ≥150ng/ml Note: patients with a suspicion of partial DPD deficiency, defined as a uracil concentration ≥ 16 ng/ml and < 150 ng/ml, will receive an adapted 1st cycle dose, according to a clinic-biological discussion. The dose can be then readapted for the second cycle according to the tolerability of the treatment during the 1st cycle.
4. Patient previously treated with chemotherapy for the neuroendocrine tumour
5. Patient have received any other antitumor therapy: chemotherapy, immunotherapy
6. Other serious diseases such as respiratory failure or congestive heart failure, angina pectoris not medically controlled; history of myocardial infarction within 6 months prior to study entry, uncontrolled hypertension and arrhythmias, concomitant severe infection or uncontrolled diabetes mellitus
7. Subjects with a history of chronic or acute hepatitis C or B infection.
8. Surgery during the 5 weeks preceding the randomization
9. History of cancer (except basal cell skin or carcinoma in situ carcinoma of the cervix) within 5 years prior to entry into the trial. But patients with cancers that have been treated more than 5 years ago and are considered as cured are eligible.
10. Neurological or psychiatric pathology that may interfere with adherence to treatment
11. Patients have received yellow fever vaccine within 30 days prior to the first dose of trial treatment.
12. Patient with pernicious anaemia and other megaloblastic anaemias secondary to the lack of Vitamin B12
13. Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
14. Hypersensitivity to study drugs or any of its excipients
15. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
16. Pregnant or breast feeding women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LV5FU2 + streptozotocin	Drug: LV5FU2; LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion); Drug: Streptozocin; streptozotocin 800 mg/m² day 1 every 14 days
Experimental: Capecitabine + temozolomide	Drug: Capecitabine; Capecitabine 750 mg/m² twice daily, days 1-14; Drug: Temozolomide; temozolomide 200 mg/m² once daily, days 10-14, every 28 days
Experimental: LV5FU2 + streptozotocin + Bevacizumab	Drug: LV5FU2; LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion); Drug: Streptozocin; streptozotocin 800 mg/m² day 1 every 14 days; Drug: Bevacizumab; bevacizumab 5 mg/kg every 14 days
Experimental: Capecitabine + temozolomide + Bevacizumab	Drug: Bevacizumab; bevacizumab 5 mg/kg every 14 days; Drug: Capecitabine; Capecitabine 750 mg/m² twice daily, days 1-14; Drug: Temozolomide; temozolomide 200 mg/m² once daily, days 10-14, every 28 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Progression Free Survival (PFS) rate	Until disease progression or unacceptable toxicity (median 24 months)

Secondary Outcome Measures

Outcome Measure	Time Frame
Toxicity (NCI-CTCAE 4.0)	Until disease progression or unacceptable toxicity

Collaborators and Investigators

• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
• Collaborators: National Cancer Institute, France

Study record dates

Study Major Dates

• Study Start (Actual): June 26, 2018
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028

Study Registration Dates

• First Submitted: November 20, 2017
• First Submitted That Met QC Criteria: November 20, 2017
• First Posted (Actual): November 22, 2017

Study Record Updates

• Last Update Posted (Actual): May 8, 2024
• Last Update Submitted That Met QC Criteria: May 7, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Antibiotics, Antineoplastic; Temozolomide; Capecitabine; Bevacizumab; Streptozocin
• Other Study ID Numbers: 2017-000741-46; 2017/2523 (Other Identifier: CSET number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No